Therapeutically, the role of ICIs has evolved differently: in NSCLC, ICIs are used across lines of therapy, both as monotherapy in PD-L1 high expressors and, more commonly, in combination with chemotherapy in the first-line setting regardless of PD-L1 status (Herbst et al., 2020; Paz-Ares et al., 2018). This evidence concerns the gene CD274 and non-small cell lung carcinoma.